| Previous Close | 72.34 |
| Open | 72.32 |
| Bid | 71.97 x 400 |
| Ask | 72.22 x 100 |
| Day's Range | 71.83 - 72.63 |
| 52 Week Range | 63.76 - 82.10 |
| Volume | 6,052,601 |
| Avg. Volume | 8,767,276 |
| Market Cap | 94.18B |
| Beta | 1.08 |
| PE Ratio (TTM) | 7.62 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.88%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Zacks•yesterday
Mylan Finalizes Settlement Agreement with DOJ for $465M
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
- Market Realist•2 days ago
Let’s Explore How Cost Leadership Provides Market Control
Firms with a structural cost advantage can either undercut competitors on price while earning similar margins, or they can charge market-level prices while earning relatively high margins.
- Zacks•2 days ago
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.
